ARVO 2023: Apellis presents research on visual function, imaging, and AIMay 3rd 2023
Caroline Baumal, MD, spoke with our onsite team at the 2023 ARVO annual meeting to share more about Apellis' presentations focusing on visual function, imaging and artificial intelligence.
ARVO 2023: The value of holographic optical coherence tomography (OCT) and continued imaging researchMay 2nd 2023
Dierck Hillmann, PhD, was interviewed by our onsite team at the 2023 ARVO annual meeting where he shared research on holographic optical coherence tomography (OCT).
ARVO 2023: Insights at the annual meeting regarding non-viral gene therapy targeting ABCA4 retinopathiesMay 2nd 2023
Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.
ARVO 2023: Research on epigenetic reprogramming to reverse aging and restore function to RGCsApril 29th 2023
Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.
ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progressionApril 29th 2023
Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).
ARVO 2023: Nanoscope Therapeutics presents data on MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosaApril 29th 2023
Nanoscope Therapeutics Inc. presented key data at the ARVO 2023 annual meeting regarding their from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, which has received both orphan drug and fast track designations from the FDA.
ARVO 2023: Using retinal imaging for early detection of diabetic retinopathy in underserved communitiesApril 29th 2023
Edmund Arthur, OD, PhD, FAAO, shared how retinal imaging can be an important tool for early detection of diabetic retinopathy in underserved communities.
ARVO 2023: Ascidian Therapeutics shares insight on new gene therapyApril 28th 2023
Our team met with Jay Barth, MD, at the 2023 ARVO annual meeting, where he shared more about the work at Ascidian Therapeutics and how the company is developing a new method to administer gene therapy.
ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meetingApril 28th 2023
D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt diseaseApril 27th 2023
Belite Bio Inc. presented 18-month data from its ongoing two-year, open-label Phase 2 clinical study of LBS-008 (Tinlarebant), a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA.
ARVO 2023: Data suggest greater retinal drying via faricimab when compared to aflibercept in wet AMD, DMEApril 27th 2023
Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.
ARVO 2023: Valitor’s Presentation at ARVO 2023 details preclinical Data on its Anti-VEGF biologic in development for durable treatment of wet AMDApril 26th 2023
VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.
ARVO 2023: Atsena Therapeutics shares latest safety and efficacy data on possible gene therapy for GUCY2D-associated Leber congenital amaurosis (LCA1)April 26th 2023
Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, a gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).
ARVO 2023: Carl Danzig, MD, FASRS shares new data on vision loss from the GATHER clinical programApril 25th 2023
Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.
ARVO 2023: T. Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmologyApril 25th 2023
At the 2023 ARVO annual meeting in New Orleans, our on-site team caught up with T. Y. Alvin Liu, MD, to discuss predictive AI and its application in ophthalmology and screening of the eyes.
ARVO 2023: Using donor tissue to identify the mechanism cell death of the RPEApril 25th 2023
Deborah Ferrington, PhD, spoke with on our on-site team at the 2023 ARVO annual meeting in New Orleans about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium (RPE).
ARVO 2023: Luxa Biotechnology shares progress of Phase 1/2a clinical trial for AMD treatmentApril 25th 2023
At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).
ARVO 2023: Association between visual impairment and neuropsychiatric symptoms of dementiaApril 24th 2023
Researchers found in their analysis that visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia, although, aging and comorbidities, among other factors, may be involved.
ARVO 2023: Optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and related dementiasApril 24th 2023
Amir H. Kashani, MD, PhD, joined us to share insights from his presentation at the 2023 ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.
ARVO 2023: Nonclinical data by Adverum Biotechnologies regarding potential treatment of wet AMDApril 24th 2023
Adverum Biotechnologies Inc. shared nonclinical data at ARVO 2023 in New Orleans that staggered, bilateral administration of Ixo-vec in NHPs was well tolerated with encouraging therapeutic activity and no signals of increased inflammation.
ARVO 2023: Ocular blood flow and its relationship to acute coronary syndromeApril 24th 2023
The team of Japanese researchers found that the choroidal MBR in the nasal region is correlated with systemic arterial stiffness and is significantly lower in patients with coronary artery multivessel disease.
ARVO 2023: Hydrogen water intake improved RBF Dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic miceApril 23rd 2023
Hydrogen-rich water may have a place in treatment of retinal degeneration. The team of investigators found that the hydrogen-rich water significantly improved the retinal blood flow (RBF) dysregulation in type 2 diabetic mice.